Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Hematology-Oncology Associates of CNY has appointed Jennifer Pichoske as chief executive officer effective February 15, 2025.

Dr. Alan C. Hartford is an expert in oncology, the field of medicine focusing on the diagnosis, treatment, prevention and ...

Sarah Anderson, oncology strategy lead director, Novotech, discusses the growing prominence of triple-negative breast cancer ...

Discover why Exact Sciences, a leading oncology diagnostics company, may see growth in the cancer diagnostics market with its ...

Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, announced today that it will present preclinical data on its ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of ...

The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...

Cambium Oncology is pleased to share that their lead drug candidate, ANT308, recently demonstrated outstanding single-agent efficacy and safety in preclinical ...

The antibody drug conjugate was approved for patients with unresectable or metastatic HER2-low or -ultralow breast cancer ...

Northwell Health partnered with Stacker to explore how a new Pap smear alternative may help prevent deaths from cervical ...

Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...